Patents Examined by Sahar Javanmard
  • Patent number: 10383883
    Abstract: A decongestant composition is provided comprising: (a) a safe and effective amount of an adrenergic compound; (b) a safe and effective amount of a steroid; and (c) a pharmaceutically-acceptable carrier. Methods of treating congestion in a human or animal subject are also provided comprising administering to the subject a composition comprising: (a) an adrenergic compound; and (b) a steroid; where the daily dose of the adrenergic compound administered to the subject is from about 1 ?g to about 800 ?g, and the daily dose of the steroid administered to the subject is from about 1 ?g to about 400 ?g.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: August 20, 2019
    Inventor: Richard A. Wandzel
  • Patent number: 10383864
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: August 20, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: David J. Lockhart, Jeff Castelli
  • Patent number: 10385050
    Abstract: The present invention is concerned with indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula I wherein Ar1, A2, R1, R2, R3, X and n are as described herein and pharmaceutically acceptable salts thereof for treatment of central nervous system disorders
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 20, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hans Hilpert, Sabine Kolczewski, Anja Limberg, Theodor Stoll
  • Patent number: 10376514
    Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: August 13, 2019
    Assignee: Dart Neuroscience (Cayman) Ltd.
    Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael I. Weinhouse
  • Patent number: 10363315
    Abstract: The present invention relates to a composition for use in the treatment of a detached retina, comprising an oil and an additive capable of increasing the extensional viscosity of the oil. The present invention also relates to a method and kit of parts for producing the composition.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: July 30, 2019
    Assignee: University of Liverpool
    Inventors: Michael Joseph Garvey, Rachel Lucinda Williams, Michael Day
  • Patent number: 10363231
    Abstract: A method of treating an ocular disorder in a subject associated with increased all-trans-retinal in an ocular tissue includes administering to the subject a therapeutically effective amount of a primary amine compound of formula (I); and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: July 30, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Krzysztof Palczewski
  • Patent number: 10357495
    Abstract: Embodiments herein are directed to topical formulations of a compound represented by the formula (I), salt, metabolite, prodrug, or hydrate thereof along with a solvent, and a base. The compound is a PDE4 inhibitor and the topical formulations may be used to treat dermatological conditions such as, but not limited to, atopic dermatitis, seborrheic dermatitis, alopecia, contact dermatitis, psoriasis, urticaria, eczema, burns, sunburn, pancreatitis, hepatitis, lichen planus, scleritis, scleroderma, dermatomyositis, itching associated with any of the preceding conditions or a combination thereof.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: July 23, 2019
    Assignees: DERMAVANT SCIENCES GMBH, EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Ambrish Vyas, Seiji Takemoto, Yoshihiro Akimoto
  • Patent number: 10350218
    Abstract: Provided herein are isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers, antibody-drug conjugates comprising them and methods of use for killing cells and treating disease.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: July 16, 2019
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Jagath R. Junutula, Sean W. Smith, Dmitry Borkin, Sylvia Degrado, Sanjeevani Ghone
  • Patent number: 10351567
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: July 16, 2019
    Assignee: Eli Lilly and Company
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen Mcnamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • Patent number: 10329314
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 25, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang
  • Patent number: 10308640
    Abstract: The present invention relates to compounds of formula I: for use in treating pulmonary arterial hypertension and associated conditions, where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl, -alkylaryl or -alkylheteroaryl; X signifies CH2, oxygen atom or sulphur atom; n is 1, 2 or 3, with the proviso that when n is 1, X is not CH2; and the individual (R)- and (S)-enantiomers or mixtures of enantiomers and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: June 4, 2019
    Assignee: Bial-Portela & CA, S.A.
    Inventors: Patricio Manuel Vieira Araújo Soares Da Silva, Maria João Macedo Da Silva Bonifácio
  • Patent number: 10301335
    Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: May 28, 2019
    Assignees: King Fahd University of Petroleum and Minerals, King Saud University
    Inventors: Said S. Al-Jaroudi, Ali Alhoshani, Muhammad Altaf, Anvarhusein Abdulkadir Isab
  • Patent number: 10292980
    Abstract: In DN-DISC1 mice, a mouse model for major mental illnesses, the model that expresses pathological phenotypes relevant to schizophrenia, mood disorders, and addiction simultaneously, the inventors of the present invention found pronounced levels of oxidative stress in the prefrontal cortex, but not in the striatum. These mice also displayed greater amounts of GAPDH-Siah1 binding, a protein-protein interaction that is activated under exposure to oxidative stress. The present inventors investigated the role of oxidative stress in other organ systems. As detailed herein, the inventors found that GAPDH-Siah1 binding was increased in mouse models of cardiac failure. It was also found, that certain novel analogs of deprenyl, significantly inhibited GAPDH-Siah1 binding in cardiac tissue.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: May 21, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Akira Sawa, Elki Takimoto, Neelam Shahani, David Kass, Toshiaki Saito
  • Patent number: 10294254
    Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: May 21, 2019
    Assignees: King Fahd University of Petroleum and Minerals, King Saud University
    Inventors: Said S. Al-Jaroudi, Ali Alhoshani, Muhammad Altaf, Anvarhusein Abdulkadir Isab
  • Patent number: 10278964
    Abstract: Methods of treating cancer related conditions using anamorelin are described.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: May 7, 2019
    Assignee: Helsinn Healthcare SA
    Inventors: William Mann, John Friend, William Polvino, Suzan Allen, Ming Lu, Elizabeth Duus, Ruben Giorgino, Enrico Baroni
  • Patent number: 10280187
    Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: May 7, 2019
    Assignees: King Fahd University of Petroleum and Minerals, King Saud University
    Inventors: Said S. Al-Jaroudi, Ali Alhoshani, Muhammad Altaf, Anvarhusein Abdulkadir Isab
  • Patent number: 10273257
    Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: April 30, 2019
    Assignees: King Fahd University of Petroleum and Minerals, King Saud University
    Inventors: Said S. Al-Jaroudi, Ali Alhoshani, Muhammad Altaf, Anvarhusein Abdulkadir Isab
  • Patent number: 10258613
    Abstract: Compositions for use in methods of treating and/or inhibiting a pathologic ocular condition, as well as methods of producing and using same, are disclosed.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: April 16, 2019
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Xi-Qin Ding, Hongwei Ma
  • Patent number: 10251851
    Abstract: Analgesic compounds for treatment of pain or fever that include a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering a compound described herein.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: April 9, 2019
    Assignee: Zeno Royalties & Milestones, LLC
    Inventor: Kevin Duane Bunker
  • Patent number: 10253000
    Abstract: The present invention refers to pyridazin-3(2H)-one derivatives of general structure I, II and III, which are selective MAO-B inhibitors, and to the use thereof for preparing medicaments intended to treat disorders derived from MAO-B hyperactivity, particularly degenerative disorders of the central nervous system (CNS), such as Parkinson's disease (PD), Alzheimer's disease (AD) and other dementias. These are pyridazin-3(2H)-one derivatives having dithiocarbamate moieties bonded to position 4, 5 or 6 through an alkyl chain of variable length (n=1, 2, 3). This invention is also directed to the preparation of said compounds.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: April 9, 2019
    Assignees: UNIVERSIDADE DE VIGO, UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
    Inventors: Ma del Carmen Terán Moldes, Pedro Besada Pereira, Tamara Costas Caamaño, Ma del Carmen Costas Lago, Noemí Vila Molares, Dolores Viña Castelao